^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Non Small Cell Lung Cancer
    Drug:Lumakras (sotorasib) (KRAS G12C inhibitor) +
    BMS-986466 (PTPN11 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    GlobeNewswire
    Title:

    BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)

    Published date:
    10/11/2022
    Excerpt:
    ...the US Food and Drug Administration (FDA) granted Fast Track designation for the investigation of BBP-398 in combination with LUMAKRAS for adult patients with previously treated, KRAS G12C-mutated, metastatic NSCLC.